Cost-utility analysis of iinsulin pumps compared to multiple daily doses of insulin in patients with type 1 diabetes mellitus in Spain;Análisis coste-utilidad de las bombas de insulina frente a múltiples dosis diarias en pacientes con diabetes mellitus tipo 1 en España

Revista Espanola de Salud Publica

Volumn 80, Issue 6, 2006, Pages 679-695

  Donlo, Ignacio Conget ^a   Contreras, David Serrano ^b   Rodríguez Barrios, José Manuel ^b   Mizrahi, Isaac Levy ^a   Abat, Conxa Castell ^c   Roze, Stephan ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b Economía de la Salud Y Reembolso   (Spain)

^c GENERALITAT DE CATALUNYA   (Spain)

^d IQVIA   (United States)

Author keywords

Cost utility; Diabetes mellitus type 1; Economic model; Insulin pump; Programmable implantable

Indexed keywords

EID: 33847084409     PISSN: 11355727     EISSN: 16969820     Source Type: Journal    
DOI: 10.1590/s1135-57272006000600008     Document Type: Article

References (58)

1. Ettaro L, Songer TJ, Zhang P, Engelgau MM: Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 2004; 22:149-64.
2. Goday A: Epidemiología de la diabetes y sus complicaciones no coronarias. Rev.Esp.Cardiol 2002;55:657-670.
3. Goday A, Serrano-Rios M: Epidemiología de la Diabetes Mellitus en España. Revisión crítica y nuevas perspectivas. Med.Clin.(Barc.) 1994;102:306-15.
4. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC: Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res.Rev 2002;18 Suppl 1:S14-S20.
5. Lenhard MJ, Reeves GD: Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch.Intern.Med. 2001;161:2293-300.
6. Pickup J, Mattock M, Kerry S: Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324:705.
7. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R: Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26:1079-87.
8. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR: Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value.Health 2003; 6:9-17.
9. Rodriguez Barrios JM: El papel de los modelos en la evaluación económica en el campo sanitario. Farm.Hosp 2004; 28:231-42.
10. Malone DC: The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines. J.Manag.Care Pharm 2005; 11:S7-10.
11. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA: The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr.Med.Res.Opin 2004; 20 Suppl 1:S5-26.
12. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA: Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr.Med.Res. Opin. 2004; 20 Suppl 1:S27-S40.
13. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC: Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am.Heart J 2000; 139:272-81.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann.Intern.Med 1995; 122:561-8.
15. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 17:703-13.
16. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321:412-9.
17. Janghorbani MB, Jones RB, Allison SP: Incidence of and risk factors for cataract among diabetes clinic attenders. Ophthalmic Epidemiol 2000; 7:13-25.
18. The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N.Engl.J.Med 1993; 329:977-86.
19. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;87:2563-9.
20. Canton A, Fernandez CM, Conget I, Carreras G, Castell C, Tresserras R: Type 1 diabetes mellitus in Catalonia: chronic complications and metabolic control ten years after onset. Med.Sci.Monit 2004; 10:CR185-CR190.
21. Instituto Nacional de Estadística. Actualizado según el IPC de los productos sanitarios. Disponible en: http://www.ine.es . Madrid: INE; 2005.
22. Desgagne A, Castilloux AM, Angers JF, LeLorier J: The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998; 13:487-97.
23. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N.Engl.J.Med. 1993;29:977-86.
24. Roel P.L.M Hoogma: Disponible en: http://www.diabetes-symposium.org/ index.php?menu=lectures&archive=0&topicid=15. Citadoel 02/04/2005.
25. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC: Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res.Rev 2002; 18 Suppl 1:S14-S20.
26. Pickup J, Mattock M, Kerry S: Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324:705.
27. Linkeschova R, Raoul M, Bott U, Berger M, Spraul M: Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet.Med 2002; 19:746-51.
28. DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289:2254-64.
29. National Institute of Clinical Excellence. Guide to the methods of technology appraisal. Londres: NICE; 2004.
30. Bruttomesso D, Pianta A, Crazzolara D, Scaldaferri E, Lora L, Guarneri G, Mongillo A, Gennaro R, Miola M, Moretti M, Confortin L, Beltramello GP, Pais M, Baritussio A, Casiglia E, Tiengo A: Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet.Med 2002; 19:628-34.
31. Costa B, Cabre J, Martin F, Pinol J, Basora J, Blade J: La escala de Framingham sobrevalora el riesgo cerebrovascular de la diabetes y el síndrome metabólico de la población española. Aten.Primaria 2005; 35:392-8.
32. Ramos R, Solanas P, Cordon F, Rohlfs I, Elosua R, Sala J, Masia R, Faixedas MT, Marrugat J: Comparación de la función de Framingham original y la calibrada del REGICOR en la predicción del riesgo coronario poblacional. Med.Clin.(Barc.) 2003; 121:521-6.
33. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, Solanas P, Cordon F, Ramos R, Sala J, Masia R, Kannel WB: An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J.Epidemiol. Community Health 2003; 57:634-8.
34. de la Pena FA, Suarez FC, Cuende M, I, Munoz RM, Garre CJ, Camafort BM, Roca VB, Alcala PJ: Control integral de los factores de riesgo en pacientes de alto y muy alto riesgo cardiovascular en España. Estudio CIFARC. Med.Clin.(Barc.) 2005; 124:44-9.
35. Aranceta J, Perez RC, Foz SM, Mantilla T, Serra ML, Moreno B, Monereo S, Millan J: Tablas de evaluación del riesgo coronario adaptadas a la población española: estudio DORICA. Med. Clin.(Barc.) 2004; 123:686-91.
36. Banegas B, Jr., Rodriguez-Artalejo F, de la Cruz Troca JJ, de Andres MB, del Rey CJ: Mortalidad relacionada con la hipertensión y la presión arterial en España. Med.Clin.(Barc.) 1999; 112:489-94.
37. Otzet I, Costa B, Franch J, Morato J, Pons P: [Cardiovascular risk and glucose metabolism: agreements and discrepancies between the WHO-85 and ADA-97 classifications]. Aten.Primaria 2002;29:205-12.
38. Latour-Perez J, Navarro-Ruiz A, Ridao-Lopez M, Cervera-Montes M: Using clopidogrel in non-STsegment elevation acute coronary syndrome patients: a cost-utility analysis in Spain. Value. Health 2004; 7:52-60.
39. Plans RP, Rovira FJ: Estudio coste-efectividad de los tratamientos farmacológicos hipolipemiantes. Med.Clin.(Barc.) 1995;105:327-33.
40. Rubio-Terres C, Rodriguez J, Bolinder B, de Pablos P: Cost-Utility Analysis of Insulin Glargine Comapred with NPH Insulin in Patients with Type 1 Diabetes in Spain. Diabetes 2004; 53.
41. Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL: ¿Qué es una tecnología sanitaria eficiente en España? Gac.Sanit 2002; 16:334-43.
42. Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med.Decis.Making 2002; 22:340-9.
43. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Burden of Disease and Injury in Australia. Bull World Health Organ. 2001;79(11):1076-84.
44. Tengs TO, Wallace A: One thousand health-related quality-of-life estimates. Med.Care 2000; 38:583-637.
45. Carrington AL MSMMKJBAJP: Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996; 32:19-25.
46. NICE. NICE National Institute for Clinical Excellence. Technology appraisal guidance - No. 53. Guidance on the use of long-acting insuiln analogues for the treatment of diabetes - insulin glargine. 1-12-2002. 2006,
47. Levy E, Gabriel S, Dinet J: The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003; 21:651-9.
48. Oliva J, Lobo F, Molina B, Monereo S: Direct health care costs of diabetic patients in Spain. Diabetes Care 2004; 2616-21.
49. Aros F, Loma-Osorio A, Alonso A, Alonso JJ, Cabades A, Coma-Canella I, Garcia-Castrillo L, Garcia E, Lopez dS, Pabon P, San Jose JM, Vera A, Worner F: Guías de actuación clínica de la Sociedad Española de Cardiología en el infarto agudo de miocardio. Rev.Esp.Cardiol 1999; 52:919-56.
50. Antoñanzas F, Anton F, Echevarria I, Juarez C: Clinica y Epidemiologia de la Insuficiencia Cardiaca Congestiva (ICC): Un analisis de Costes. Clinica cardiovascular 1998; 16:27-34.
51. Lamas J, Alonso M, Saavedra J, Garcia-Trio G, Rionda M, Ameijeiras M: Costes de la diálisis crónica en un hospital. público: mitos y realidades. Nefrologia. 2001; 21:283-94.
52. Real Decreto 1247/2002 de 3 de diciembre por el que se regula la gestion del fondo de cohesion sanitaria. BOE núm 290: 04/12/2004.
53. De Alvaro F, Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA. Coste-efectividad de irbesartan en pacientes hipertensos con nefropatía diabética tipo II: una perspectiva española. Nefrología 2004; 23:231-8.
54. Instituto de Salud Carlos III: Analisis coste-efectividad de diferentes estrategias para el cribado y tratamiento de la retinopatia diabetica en pacientes con diabetes mellitus. Madrid: Ministerio de Sanidad y onsumo; 2004.
55. Castells X, Alonso J, Castilla M, Ribo C, Cots F, Anto JM: Outcomes and costs of outpatient and inpatient cataract surgery: a randomised clinical trial. J.Clin.Epidemiol 2001; 54:23-9.
56. Ghatnekar O, Persson U, Willis M, Odegaard K: Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001; 19:767-78.
57. Hart WM, Espinosa C, Rovira J: A simulation model of the cost of the incidence of IDDM in Spain. Diabetologia 1997; 40:311-8.
58. Curtis JR, To T, Muirhead S, Cummings E, Daneman D: Recent trends in hospitalization for diabetic ketoacidosis in ontario children. Diabetes Care 2002; 25:1591-6.